Dr. Reddy’s Laboratories and Takeda Pharmaceutical Company have entered into an exclusive agreement to promote and distribute QDENGA, Takeda’s dengue vaccine, in India’s private market.

The agreement covers vaccination for both children and adults. Subject to applicable local regulatory processes, QDENGA is expected to become available in India during the first half of 2027.

The dengue vaccine received marketing authorisation from the Central Drugs Standard Control Organization (CDSCO) in July 2026 for individuals aged 4 to 60 years.
Under the agreement, Dr. Reddy’s will exclusively handle private-market distribution of the vaccine in India. Its responsibilities will also include disease awareness initiatives and engagement with healthcare professionals.

Takeda will continue to retain rights related to the public market, along with legal ownership and overall medical and brand oversight.

The planned private-market launch is subject to the completion of local regulatory processes. The agreement is intended to expand access to QDENGA through India’s private healthcare and vaccination market.

Dengue is a mosquito-borne viral infection that can cause symptoms ranging from fever and body aches to severe disease requiring hospitalisation. Vaccination is one component of broader dengue prevention, which also includes measures to reduce mosquito breeding and exposure.

The planned introduction of QDENGA follows its regulatory approval for the specified age group in India. Further details on pricing, distribution and the exact launch date are expected closer to its commercial availability.